Céline K.
- Country
- France
- Department
- Onco-hematology
Research Overview
- Evaluation of Prolonged Anticoagulation with Enoxaparin and Apixaban for Venous Thromboembolism Prevention in Autoimmune Hemolytic Anemia Patients
- Phase 3 Study of Isatuximab, Lenalidomide, and Dexamethasone ± Bortezomib in Non-Frail, Transplant-Ineligible Elderly Patients with Newly Diagnosed Multiple Myeloma
- Evaluation of Dexamethasone as Initial Therapy in Advanced Relapsed/Refractory Multiple Myeloma: A Randomized, Open-Label, Non-Inferiority Trial
Data & Insights
Has run more than one trial at 70 of 106 partner sites.
Specializations
Hematologic Disorders
The investigator specializes in treating autoimmune hemolytic anemia, with particular focus on preventing complications through anticoagulation therapy. Their research encompasses preventive approaches for venous thromboembolism in AIHA patients.
- Autoimmune hemolytic anemia management
- Thromboembolism prevention
- Anticoagulation protocols
Multiple Myeloma Treatment
Extensive work in multiple myeloma therapeutics, focusing on novel treatment approaches for both newly diagnosed and relapsed/refractory cases. The investigator studies innovative drug combinations and treatment strategies for various patient populations.
- Advanced treatment protocols
- Elderly patient care
- Salvage therapy optimization
Innovative Therapies
Leading research in targeted therapeutic approaches for multiple myeloma, including evaluation of new drug combinations such as elranatamab-lenalidomide and daratumumab-based regimens. Special interest in maintenance therapy optimization and minimal residual disease assessment.
- Novel drug combinations
- Consolidation strategies
- Treatment personalization
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.